Mizuho Medy Co., Ltd. (4595) AI Stock Analysis

0 Followers

Mizuho Medy Co., Ltd.

(TSE/TYO:4595)

Select Model

Rating:78Outperform

Price Target:JPY 1,906.00▲(10.88% Upside)

Action:reiterated

Date:11/07/26

Strong financial performance from high profitability and a debt-free balance sheet is the primary driver. Attractive low P/E and high dividend yield provide additional support, while technicals reflect near-term weakness offset by oversold signals.

Positive Factors

Recurring consumables modelMizuho Medy’s reagent and test-kit model creates repeat purchasing as laboratories conduct ongoing clinical testing. This recurring consumables exposure can support durable demand, improve customer retention, and provide a foundation for revenue resilience as testing volumes continue.

Negative Factors

Normalized growth and marginsRecent growth is modest compared with the company’s earlier peak performance, while lower margins indicate reduced earnings leverage from revenue. If this normalization persists, Mizuho Medy may have less capacity to compound profits and could face a slower improvement trajectory.

Mizuho Medy Co., Ltd. (4595) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 32.74B
Dividend Yield: 5.82%
Average Volume (3M): 77.59K
Price to Earnings (P/E): 10.1
Beta (1Y): 0.41
Revenue Growth: 0.75%
EPS Growth: -2.33%
Country: Japan
Employees: 193
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Mizuho Medy Co., Ltd. Business Overview & Revenue Model

Company Description

Established in 1977 and headquartered in Tosu, Japan, Mizuho Medy Co.,Ltd. specializes in the research, development, production, and distribution of in-vitro diagnostic solutions, complemented by scientific and technical information services. While i...

How the Company Makes Money

The company primarily makes money by selling IVD products, with revenue largely driven by diagnostic reagents and test kits that are consumed repeatedly as tests are performed. A typical revenue model in this business consists of (1) recurring consum...

Mizuho Medy Co., Ltd. Financial Statement Overview

Summary

Strong profitability with high margins and an exceptionally robust balance sheet featuring zero debt and growing equity, though recent declines in cash flow generation introduce some caution.

Income Statement

85Very Positive

Balance Sheet

90Very Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.82B	11.26B	11.43B	10.99B	17.58B	12.89B
Gross Profit	7.40B	7.78B	8.04B	8.03B	14.05B	9.61B
EBITDA	4.44B	4.91B	5.10B	5.40B	11.26B	6.87B
Net Income	3.23B	3.42B	3.77B	3.77B	7.84B	4.82B
Balance Sheet
Total Assets	20.99B	22.38B	20.73B	18.95B	19.10B	12.19B
Cash, Cash Equivalents and Short-Term Investments	13.06B	10.82B	11.25B	10.13B	8.70B	4.33B
Total Debt	0	0	0	0	0	0
Total Liabilities	2.43B	3.69B	3.37B	3.27B	4.82B	4.16B
Stockholders Equity	18.55B	18.68B	17.35B	15.68B	14.28B	8.03B
Cash Flow
Free Cash Flow	0	1.70B	3.05B	3.73B	5.99B	5.44B
Operating Cash Flow	0	1.96B	3.35B	3.99B	6.17B	5.60B
Investing Cash Flow	0	-7.28B	-307.00M	-270.45M	-1.55B	-159.74M
Financing Cash Flow	0	-2.08B	-2.09B	-2.38B	-1.57B	-1.16B

Mizuho Medy Co., Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price1719.00

Price Trends

50DMA1717.78Positive

100DMA1696.43Positive

200DMA1716.09Positive

Market Momentum

MACD-1.68Negative

RSI51.49Neutral

STOCH74.80Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4595, the sentiment is Positive. The current price of 1719.00 is above the 20-day moving average (MA) of 1715.05, above the 50-day MA of 1717.78, and above the 200-day MA of 1716.09, indicating a bullish trend. The MACD of -1.68 indicates Negative momentum. The RSI at 51.49 is Neutral, neither overbought nor oversold. The STOCH value of 74.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4595.

Mizuho Medy Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JP:4595 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
JP:4595	78Outperform	JPY 33.26B	10.15	―	5.82%	0.75%	-2.33%
JP:4554	69Neutral	JPY 48.97B	16.85	5.56%	2.80%	20.72%	-10.35%
JP:4886	69Neutral	JPY 58.28B	11.79	―	3.01%	―	9.04%
JP:4534	68Neutral	JPY 114.00B	11.03	7.68%	2.46%	15.85%	60.55%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
JP:4539	47Neutral	JPY 5.52B	-11.50	―	3.30%	0.31%	-194.72%
JP:4892	42Neutral	JPY 5.30B	-6.32	―	―	364.72%	18.43%

* General Sector Average

Performance Comparison

JP:4595 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:4595	Mizuho Medy Co., Ltd.	1719.00	193.57	12.69%
JP:4554	Fuji Pharma Co., Ltd.	1857.00	225.16	13.80%
JP:4534	Mochida Pharmaceutical Co., Ltd.	3355.00	123.57	3.82%
JP:4539	Nippon Chemiphar Co., Ltd.	1515.00	34.18	2.31%
JP:4886	ASKA Pharmaceutical Holdings Co., Ltd.	2160.00	185.51	9.40%
JP:4892	Cyfuse Biomedical K.K.	514.00	-67.00	-11.53%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Mizuho Medy Co., Ltd. AI Stock Analysis